ClinicalTrials.gg
CompletedNCT05470829Updated Jul 22, 2022

A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R

A Phase 1 interventional study of ZM-H1505R and ZM-H1505R Placebo in Healthy Volunteers and Hepatitis B, Chronic, sponsored by Shanghai Zhimeng Biopharma, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by Shanghai Zhimeng Biopharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2021, 5 years ago, and no results have been posted to the registry.
  • Registered 1 year 1 month after the study started (first participant enrolled May 2021, registered Jul 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
236th of 273
42 · median 120
Started
2021
with 24 others
Phase 1
50 of 375
16 open now
Registered
241st of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 236th largest by enrollment of the 273 interventional ones that give a count, is one of 25 that started in 2021, is one of 50 in phase 1, and was the 241st registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This phase Ib study included two parts in which Part I was to evaluate the safety and bridge for PK among healthy Chinese subjects and Part II were about study among Chinese chronic hepatitis B virus-infected patients. Study of Part II was carried out following the safety assessment and racial difference evaluation in Part I.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multiple-dose phase Ib study.

It aimed in this study to evaluate the safety and tolerability and to characterize the pharmacokinetics of ZM-H1505R among Chinese healthy subjects following single and multiple doses administration, and to assess whether there are ethnic differences in PK characteristic among Chinese and American healthy subjects. Study was also conducted to evaluate the safety and tolerability, to characterize the pharmacokinetics and to assess the preliminary pharmacodynamics of ZM-H1505R following multiple ascending dose administration among chronic hepatitis B virus-infected patients; the PK/PD model was established among adults to provide a basis for the oral doses determination in subsequent clinical studies of ZM-H1505R.

Part I: Study among healthy subjects for safety evaluation and PK bridging Based on the PK results among American healthy subjects in Phase Ia study, 75 mg (cohort 1) was selected for PK bridging. Twelve healthy subjects were enrolled, of which 8 subjects received ZM-H1505R and 4 subjects received placebo.

Part II: Study among chronic hepatitis B virus-infected patients Subjects in four cohorts (scheduled as cohort 2, 50 mg; cohort 3, 100 mg; cohort 4, 200 mg; cohort 5, 300 mg) were enrolled in sequence from 50 mg dose group (cohort 2). Dose ascending was continued when safety evaluation on Day 8 showed that the lower dose could be tolerated. Based on the results of PK and tolerability and PD, dose ascending to 300 mg dose group (cohort 5) from 200 mg dose group (cohort 4) was discontinued determined by sponsor and investigators. Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).

03

Conditions studied

  • Healthy Volunteers
  • Hepatitis B, Chronic

Browse trials for

Keywords

  • Hepatitis B, Chronic
  • randomized
  • double-blind
  • placebo-controlled
  • phase Ib
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to sign Inform Consent Forms before study, and fully understand the study contents, process and potential adverse reactions;
  • Able to complete the study in compliance with the protocol;
  • Subjects (including their partners) agreed to adopt effective measurements from screening to 6 months after the last administration.

Part I Proprietary:

  • Male and female subjects between 18 and 50 years of age, inclusive;
  • At least 50 kg for male subjects, 45 kg for female, with a (BMI) between 18-28 ;
  • Normal or abnormal but of no clinical significance results for physical examination and vital signs.

Part II Proprietary::

  • Male and female subjects between 18 and 65 years of age, inclusive;
  • At least 50 kg for male subjects, 45 kg for female subjects, with a Body Mass Index (BMI) between 18-35 kg/m2, inclusive, BMI = weight (kg) / height 2 (m2);
  • Any proof of infection more than 6 months (including outpatient/inpatient medical records, HBV DNA, HBsAg test sheets, etc.); or with IgM HBcAb negative and HBsAg positive at screening;
  • No history of therapy including interferon/nucleoside or analog at screening, or discontinuation for more than 1 year from interferon therapy or more than 6 months from nucleoside analog therapy;
  • HBV DNA ≥ 2×105 IU/mL for HBeAg-positive patients and HBV DNA ≥ 2×104 IU/mL for HBeAg-negative patients at screening;
  • Serum lower than 5× at screening.

Exclusion criteria

Exclusion Criteria:

  • Major trauma or surgery within 3 months before screening;
  • History of treatment that may interfere with drug absorption (e.g, subtotal gastrectomy);
  • Blood donation or massive blood loss (> 450 mL) within 3 months prior to screening;
  • Any history of allergy suspected to be due to any component of the study drug, or allergic constitution (allergy to multiple drug and food);
  • A history of narcotic drugs intake or alcohol abuse ;
  • Acute infection within 2 weeks before screening;
  • Suffering from serious diseases of the circulatory, respiratory, urinary, vascular, endocrine, immune, mental and nervous systems;
  • History of myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, heart failure of grade III or IV, or stroke within 6 months prior to screening;
  • Patients with existing malignant tumors (except for skin non-melanoma, cervical intraepithelial neoplasia, thyroid tumor, breast tumor, etc. after treatment with no signs of recurrence);
  • Any surgery or hospitalization anticipated during the study;
  • Treatment history of , immunomodulators (thymosin) and cytotoxic drugs within 6 months before study administration;
  • Medication history of definitely strong inhibitors or inducers within 2 weeks before screening;
  • Involved in any other study drug administration or clinical study of medical devices within 1 month before screening; Involved in any clinical study of virus nucleocapsid inhibitors in the past;
  • Any abnormality of not suitable for the study judged by physician;
  • Positive pregnancy test results or subject is lactating for female subjects;
  • Positive test results of -Ab, HCV core antigen and HCV RNA (PCR); or antibody; or Treponema pallidum antibody further confirmed by rapid plasma reagin (RPR) test;
  • Consumption of chocolate or any diets containing caffeine or rich in xanthine, or any alcohol-containing products within 48 h before the initial administration;
  • Positive results of drug abuse tests (morphine, marijuana) or alcohol breath tests;
  • Other conditions in which subjects are not suitable for the study in the opinion of investigators.

Part I Proprietary:

  • More than 5 cigarettes everyday within 1 month before the study;
  • Intake of any prescription or over-the-counter (OTC) drugs, vitamin, herbs, other inappropriate diet or supplements in opinion of investigators within 7 days before screening;
  • Positive HBsAg test results;
  • Any abnormalities in laboratory tests.

Part II Proprietary :

  • Estimated (eGFR) ˂ 60 mL/min/1.73 m2 based on serum creatinine and formula for modification of diet in renal disease (MDRD) based on values at screening;
  • Patients with clinically significant acute or chronic liver disease not caused by HBV infection (including but not limited to alcoholic liver disease, severe or higher non-alcoholic fatty liver disease, liver disease, Gilbert syndrome or other hereditary liver disease, drug-induced liver disease, etc. );
  • Liver cirrhosis at clinical consideration or/and liver stiffness measurements (LSM) ≥ 12.4 kPa (for patients with greater than the , LSM ≥ 17.5 kPa); 27) Patients with clinically significant cardiac arrhythmias; history of risk factors for Torsade de Pointes (TdP) syndrome;
  • Uncontrolled hypertension with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at screening;
  • Patients with type I diabetes, or with newly diagnosed or poorly controlled type II diabetes ( > 8.5%);
  • \< 50%.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part 1 75mg ZM-H1505R or placebo

    75 mg was selected for PK bridging.Twelve healthy subjects were enrolled,of which 8 subjects received ZM-H1505R and 4 subjects received placebo. Subjects were administrated in the morning under fasting conditions on Day 1 and afterwards Day 4 - Day 14 once daily,i.e. after 3-day washout period and followed by 11-day consecutive administration.Safety and tolerability evaluation was performed on Day 3,Day 6,Day 10 and Day 17 after the initial administration. Two sentinel subjects (one male and one female) were enrolled to reveived ZM-H1505R.When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects,and study drug concentration of sentinel subjects after the initial administration had been analysed so that PK sampling timepoints for the remaining subjects was determined, the remaining 10 subjects were enrolled to receive ZM-H1505R or placebo at a 3:2 ratio in a randomized manner.

    Drug: ZM-H1505R · Other: ZM-H1505R Placebo

  • Experimental
    Cohort 1 of Part 2 50mg ZM-H1505R or placebo

    Subjects were enrolled in sequence from 50 mg dose group (cohort 1). Dose ascending was continued when safety evaluation on Day 8 showed that the lower dose could be tolerated. Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2). Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions. Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner.

    Drug: ZM-H1505R · Other: ZM-H1505R Placebo

  • Experimental
    Cohort 2 of Part 2 100mg ZM-H1505R or placebo

    Subjects were enrolled in sequence from 100 mg dose group (cohort 2). Dose ascending was continued when safety evaluation on Day 8 showed that the lower dose could be tolerated. Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2). Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions. Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner.

    Drug: ZM-H1505R · Other: ZM-H1505R Placebo

  • Experimental
    Cohort 3 of Part 2 200mg ZM-H1505R or placebo

    Subjects were enrolled in sequence from 200 mg dose group (cohort 3). Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2). Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions. Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner.

    Drug: ZM-H1505R · Other: ZM-H1505R Placebo

Interventions

  • DrugZM-H1505R

    Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14 Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28 Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28 Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28

  • OtherZM-H1505R Placebo

    Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14 Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28 Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28 Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of ZM-H1505R among Chinese healthy subjects

    12 healthy subjects with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatmen

    Time frame: 42 days

  2. Pharmacokinetics indicators

    PK parameters of plasma ZM-H1505R in 12 healthy subjects

    Time frame: 42 days

  3. Pharmacodynamics indicators

    PK parameters of plasma ZM-H1505R in 30 chronic hepatitis B virus-infected patients

    Time frame: 56 days

  4. To evaluate the safety and tolerability of ZM-H1505R among chronic hepatitis B virus-infected patients

    30 chronic hepatitis B virus-infected patients with Abnormal Laboratory Values and/or Adverse Events That Are

    Time frame: 56 Days

07

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Nov 2021, 5 months.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 5 months is below that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2022
First posted
Jul 22, 2022
StartActual
May 27, 2021
Primary completionActual
Nov 17, 2021
CompletionActual
Nov 17, 2021
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05470829
Lead sponsor
Shanghai Zhimeng Biopharma, Inc.
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
May 27, 2021
Primary completion
Nov 17, 2021
Completion
Nov 17, 2021
Last update
Jul 22, 2022

Study contacts

Junqi Niu
principal investigator · The First Hospital of Jilin University
Yanhua Ding
principal investigator · The First Hospital of Jilin University
Hongxin Piao
principal investigator · Yanbian University Affiliated Hospital (Yanbian Hospital)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion